Sign in to view content

A Phase 2 Safety and Efficacy Trial of AU-011, a Virus-Like Drug Conjugate, With Dose Escalation and Randomized Masked Expansion in Uveal Melanoma

Prithvi Mruthyunjaya, MD, MHS

Video
Published 2021

Related

Baseline Factors Associated With 1-Year Outcomes in Phase III Comparison of SB11 (Approved Ranibizumab Biosimilar) With Reference Ranibizumab in nAMD
Neil M. Bressler, MD
Annual Meeting Talks
2022
Canadian Treat-and-Extend Trial With Ranibizumab in nAMD Patients: CANTREAT 36-Month Extension Results
Peter J. Kertes, MD, FRCS(C)
Annual Meeting Talks
2020
Prospective Randomized Trial of Treat-and-Extend Intravitreal Aflibercept for Radiation Retinopathy: One-Year Outcomes
Amy C. Schefler, MD FACS FASRS
Annual Meeting Talks
2022

Category: Ocular Oncology

See more